alexa Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.


Journal of Surgery

Author(s): Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA,

Abstract Share this page

Abstract Calcimimetics increase the sensitivity of parathyroid calcium-sensing receptors to extracellular calcium, thereby reducing PTH secretion. This multicenter, randomized, double-blind, placebo-controlled study assessed the ability of the oral calcimimetic cinacalcet HCl to achieve long-term reductions in serum calcium and PTH concentrations in patients with primary hyperparathyroidism (HPT). Patients (n = 78) were randomized to cinacalcet or placebo. Cinacalcet was titrated from 30-50 mg twice daily during a 12-wk dose-titration phase. Efficacy was assessed during 12-wk maintenance and 28-wk follow-up phases. The primary endpoint was the achievement of normocalcemia [serum calcium
  • DOI: 10.1210/jc.2004-0842
  • This article was published in J Clin Endocrinol Metab and referenced in Journal of Surgery

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Relevant Topics

    Peer Reviewed Journals
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version